Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease

ABSTRACT Bedaquiline (BDQ), a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections that no longer respond to conventional drugs. While investigating the off-label use of BDQ as salvage therapy, seven of 13 patients with Mycobacterium intracellulare lung disease had an initial microbiological response and then relapsed. Whole-genome comparison of pretreatment and relapse isolates of M. intracellulare uncovered mutations in a previously uncharacterized locus, mmpT5. Preliminary analysis suggested similarities between mmpT5 and the mmpR5 locus, which is associated with low-level BDQ resistance in M. tuberculosis. Both genes encode transcriptional regulators and are adjacent to orthologs of the mmpS5-mmpL5 drug efflux operon. However, MmpT5 belongs to the TetR superfamily, whereas MmpR5 is a MarR family protein. Targeted sequencing uncovered nonsynonymous mmpT5 mutations in isolates from all seven relapse cases, including two pretreatment isolates. In contrast, only two relapse patient isolates had nonsynonymous changes in ATP synthase subunit c (atpE), the primary target of BDQ. Susceptibility testing indicated that mmpT5 mutations are associated with modest 2- to 8-fold increases in MICs for BDQ and clofazimine, whereas one atpE mutant exhibited a 50-fold increase in MIC for BDQ. Bedaquiline shows potential for the treatment of M. intracellulare lung disease, but optimization of treatment regimens is required to prevent the emergence of mmpT5 variants and microbiological relapse.

[1]  L. Hall,et al.  Evaluation of the MicroSeq System for Identification of Mycobacteria by 16S Ribosomal DNA Sequencing and Its Integration into a Routine Clinical Mycobacteriology Laboratory , 2003, Journal of Clinical Microbiology.

[2]  Foram A. Thakkar,et al.  Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease. , 2015, Chest.

[3]  B. D. de Jong,et al.  Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline , 2014, PloS one.

[4]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[5]  K. Andries,et al.  Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in Mycobacteria , 2006, Antimicrobial Agents and Chemotherapy.

[6]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[7]  Shane S. Sturrock,et al.  Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data , 2012, Bioinform..

[8]  L. Eckhardt-Strelau,et al.  Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline , 2015, Science Advances.

[9]  P. Verhasselt,et al.  In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor , 2007, Antimicrobial Agents and Chemotherapy.

[10]  K. Andries,et al.  ATP Synthase Inhibition of Mycobacterium avium Is Not Bactericidal , 2009, Antimicrobial Agents and Chemotherapy.

[11]  Eduardo Gotuzzo,et al.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.

[12]  Sergey I. Nikolenko,et al.  SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing , 2012, J. Comput. Biol..

[13]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[14]  E. Pontali,et al.  Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence , 2016, European Respiratory Journal.

[15]  A. Pain,et al.  Identification of a Novel Conjugative Plasmid in Mycobacteria That Requires Both Type IV and Type VII Secretion , 2014, mBio.

[16]  Jon Cohen,et al.  Infectious disease. Approval of novel TB drug celebrated--with restraint. , 2013, Science.

[17]  M. Behr,et al.  Extensive Genomic Polymorphism within Mycobacterium avium , 2004, Journal of bacteriology.

[18]  Koen Andries,et al.  Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis , 2016, Antimicrobial Agents and Chemotherapy.

[19]  Chang Ki Kim,et al.  Mycobacterium paraintracellulare sp. nov., for the genotype INT-1 of Mycobacterium intracellulare. , 2016, International journal of systematic and evolutionary microbiology.

[20]  L. Rigouts,et al.  Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. , 2015, The Journal of antimicrobial chemotherapy.

[21]  R. Wallace,,et al.  Mycobacterial Interspersed Repetitive-Unit–Variable-Number Tandem-Repeat (MIRU-VNTR) Genotyping of Mycobacterium intracellulare for Strain Comparison with Establishment of a PCR-Based Database , 2012, Journal of Clinical Microbiology.

[22]  Foram A. Thakkar,et al.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex , 2016, Antimicrobial Agents and Chemotherapy.

[23]  E. Pauli,et al.  Evaluation of the Pharmacokinetic Interaction between Repeated Doses of Rifapentine or Rifampin and a Single Dose of Bedaquiline in Healthy Adult Subjects , 2014, Antimicrobial Agents and Chemotherapy.

[24]  K. Andries,et al.  Rates and Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor , 2009, Antimicrobial Agents and Chemotherapy.

[25]  Raquel Tobes,et al.  The TetR Family of Transcriptional Repressors , 2005, Microbiology and Molecular Biology Reviews.

[26]  R. Wallace,,et al.  In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates , 2013, Journal of Clinical Microbiology.

[27]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[28]  A. Lucarelli,et al.  Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. , 2009, Tuberculosis.

[29]  K. Andries,et al.  Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[30]  S. Cole,et al.  Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.

[31]  Michael J E Sternberg,et al.  The Phyre2 web portal for protein modeling, prediction and analysis , 2015, Nature Protocols.

[32]  C. Daley,et al.  The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. , 2012, American journal of respiratory and critical care medicine.

[33]  E. Caumes,et al.  Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Dirk Bald,et al.  Diarylquinolines target subunit c of mycobacterial ATP synthase. , 2007, Nature chemical biology.

[35]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.

[36]  M. Drancourt,et al.  Genotyping of Mycobacterium avium complex organisms using multispacer sequence typing. , 2010, Microbiology.

[37]  Alexey Drozdetskiy,et al.  JPred4: a protein secondary structure prediction server , 2015, Nucleic Acids Res..

[38]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .